Skip to content
PICO Portalanswers from OpenAlex

Lipidomics reveals immune-related adverse events in NSCLC patients receiving immune checkpoint inhibitor

PaperCitations, authors & open-access status

Lipidomics reveals immune-related adverse events in NSCLC patients receiving immune checkpoint inhibitor is a paper indexed in PICO Portal from OpenAlex.

How many citations does Lipidomics reveals immune-related adverse events in NSCLC patients receiving immune checkpoint inhibitor have?

PICO Portalcitation count

Lipidomics reveals immune-related adverse events in NSCLC patients receiving immune checkpoint inhibitor has 19 citations in the OpenAlex counts PICO Portal stores.

When was Lipidomics reveals immune-related adverse events in NSCLC patients receiving immune checkpoint inhibitor published?

PICO Portalyear

Lipidomics reveals immune-related adverse events in NSCLC patients receiving immune checkpoint inhibitor has 2023 year in the PICO Portal index.

What is the open-access status of Lipidomics reveals immune-related adverse events in NSCLC patients receiving immune checkpoint inhibitor?

PICO Portaloa status

Lipidomics reveals immune-related adverse events in NSCLC patients receiving immune checkpoint inhibitor has closed oa status in the PICO Portal index.

What is the DOI of Lipidomics reveals immune-related adverse events in NSCLC patients receiving immune checkpoint inhibitor?

PICO Portaldoi

The DOI for Lipidomics reveals immune-related adverse events in NSCLC patients receiving immune checkpoint inhibitor is on the source record.

What is the PMID of Lipidomics reveals immune-related adverse events in NSCLC patients receiving immune checkpoint inhibitor?

PICO Portalpmid

The PMID for Lipidomics reveals immune-related adverse events in NSCLC patients receiving immune checkpoint inhibitor is on the source record.

What is the OpenAlex record for Lipidomics reveals immune-related adverse events in NSCLC patients receiving immune checkpoint inhibitor?

PICO Portalopenalex

The OpenAlex for Lipidomics reveals immune-related adverse events in NSCLC patients receiving immune checkpoint inhibitor is on the source record.

Related on PICO Portal

470M+ articles · 14-day free trial